Intercept (ICPT) Waiting for Catalysts - Cowen

FBR Slashes PT on Intercept Pharma (ICPT) to $192; Eases Market Opportunity Outlook for OCA

FBR & Co. is cutting its price target on Market Perform-rated Intercept Pharma (Nasdaq: ICPT) from $273 to $192 with the firm saying it is "moderating" is view on OCA.

Analyst Vernon Bernardino said the new price target is "driven by our view that the market opportunity of Intercepts investigational liver disease drug, obeticholic acid (OCA), is smaller... More

Intercept Pharma (ICPT) Advances to Session High

Intercept Pharma (NASDAQ: ICPT) hit session highs Tuesday morning, rising 12%.

Needham & Company Reiterates Buy on Intercept (ICPT) Following Q3 Update

Needham & Company analyst Alan Carr reiterating a Buy rating and $500 price target on Intercept Pharmaceuticals (NASDAQ: ICPT) following earnings and the company's corporate update today.

Carr commented, "Intercept mgmt provided a 3Q15 corporate update this morning. Key upcoming milestones include the Obeticholic... More

Intercept Pharmaceuticals (ICPT) Outlook Unchanged Following Earnings - Baird

Baird analyst Brian Skorney reiterated an Outperform rating and $346 price target on Intercept Pharmaceuticals (NASDAQ: ICPT) saying the outlook is unchanged following earnings.

Skorney commented, "3Q15 served as more of a housekeeping event than anything else. The company focused on discussing preparation... More

Intercept Pharma (ICPT) Posts Narrwer-than-Expected Q3 Loss

Intercept Pharma (NASDAQ: ICPT) reported Q3 EPS of ($2.10), $0.65 better than the analyst estimate of ($2.75). Revenue for the quarter came in at $445 thousand versus the consensus estimate of $420 thousand.

As of September 30, 2015, Intercept had cash, cash equivalents and investment securities available for sale of approximately... More